Search results for "pharmacogenetics."

showing 10 items of 79 documents

Cytotoxicity of the bisphenolic honokiol from Magnolia officinalis against multiple drug-resistant tumor cells as determined by pharmacogenomics and …

2014

A main problem in oncology is the development of drug-resistance. Some plant-derived lignans are established in cancer therapy, e.g. the semisynthetic epipodophyllotoxins etoposide and teniposide. Their activity is, unfortunately, hampered by the ATP-binding cassette (ABC) efflux transporter, P-glycoprotein. Here, we investigated the bisphenolic honokiol derived from Magnolia officinalis. P-glycoprotein-overexpressing CEM/ADR5000 cells were not cross-resistant to honokiol, but MDA-MB-231 BRCP cells transfected with another ABC-transporter, BCRP, revealed 3-fold resistance. Further drug resistance mechanisms analyzed study was the tumor suppressor TP53 and the epidermal growth factor recepto…

HonokiolATP Binding Cassette Transporter Subfamily BPharmaceutical ScienceBiologyPharmacologyLignanschemistry.chemical_compoundGefitinibCell Line TumorDrug DiscoverymedicineATP Binding Cassette Transporter Subfamily G Member 2HumansEpidermal growth factor receptorCytotoxicityPI3K/AKT/mTOR pathwayOligonucleotide Array Sequence AnalysisPharmacologyBiphenyl CompoundsTransfectionbiology.organism_classificationAntineoplastic Agents PhytogenicDrug Resistance MultipleNeoplasm ProteinsErbB ReceptorsMolecular Docking SimulationMagnolia officinalisComplementary and alternative medicinechemistryDrug Resistance NeoplasmMagnoliaPharmacogeneticsbiology.proteinMolecular MedicineATP-Binding Cassette TransportersErlotinibTumor Suppressor Protein p53Transcriptomemedicine.drugSignal TransductionPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Watch out for diabetes: Less education but let's get moving, let's eat less!

2016

Lifestyle interventionmedicine.medical_specialtyClinical markers of cardiovascular disease030204 cardiovascular system & hematologyDiabete03 medical and health sciences0302 clinical medicinePatient Education as TopicRisk FactorsDiabetes mellitusLifestyle interventionDiabetes MellitusmedicineInternal MedicineHumansHypoglycemic Agents030212 general & internal medicineExercisebusiness.industrymedicine.diseaseDietCardiovascular DiseasesPharmacogeneticsFamily medicinePhysical therapySedentary BehaviorbusinessDiet Therapy
researchProduct

Pharmacogenetic Study of ABCB1 and CYP3A5 Genes During the First Year Following Heart Transplantation Regarding Tacrolimus or Cyclosporine Levels

2011

Pharmacogenetics explains part of the interindividual variability in drug responses. Many published works about the effects of single nucleotide polymorphisms (SNPs) on immunosuppressive drug blood levels present contradictory results. We evaluated the SNPs in ABCB1 (glycoprotein P) and CYP3A5 (metabolic enzyme) genes, seeking correlate them with tacrolimus or cyclosporine levels during the first year after heart transplantation. One blood sample was obtained from each of 41 patients: 26 treated with cyclosporine and 15 with tacrolimus. We characterize the SNPs rs1045642, 1128503, 2032582, 2235013, 2235033, 2229109, 3213619, 9282564 in ABCB1 and rs10264272, 776746 in CYP3A5 genes using the …

Linkage disequilibriummedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BGenotypemedicine.medical_treatmentSingle-nucleotide polymorphismBiologyPharmacologyPolymorphism Single NucleotideGastroenterologyLinkage DisequilibriumTacrolimusGene FrequencyInternal medicineGenotypemedicineCytochrome P-450 CYP3AHumansDrug Dosage CalculationsATP Binding Cassette Transporter Subfamily B Member 1CYP3A5Heart transplantationTransplantationTacrolimusPhenotypeImmunosuppressive drugPharmacogeneticsSpainCyclosporineHeart TransplantationSurgeryDrug MonitoringImmunosuppressive AgentsPharmacogeneticsTransplantation Proceedings
researchProduct

The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients

2008

Background: Tacrolimus is a substrate of cytochrome P-450 (CYP) 3A enzyme and of the drug transporter ABCBl. We have investigated the effects of possible relevant CYP3A5 and ABCBl single nucleotide polymorphisms (SNPs) present in both donors and recipients on tacrolimus blood levels achieved in a population of 32 Caucasian liver transplant patients. Material/Methods: At 1, 3 and 6 months after transplantation, tacrolimus doses (mg/kg/day) and trough blood levels (C0) were determined. Polymerase chain reaction followed by restriction fragment length polymorphism analysis was used for gen-otyping CYP3A5*3 [6986A>G] as well as ABCBl at exons 21 [2677G>T] and 26 [3435C>T]. Results:87.5…

MaleCYP3A5ATP Binding Cassette Transporter Subfamily BGenotypeHomozygoteABCB1Polymorphism Single NucleotideTacrolimusWhite PeopleLiver Transplantationliver transplantPharmacogeneticssingle nucleotide polymorphismTacrolimuSettore BIO/14 - FarmacologiaCytochrome P-450 CYP3AHumansFemaleATP Binding Cassette Transporter Subfamily B Member 1Tacrolimus; single nucleotide polymorphisms; CYP3A5; ABCB1; liver transplantImmunosuppressive Agents
researchProduct

Polymorphisms of pro-inflammatory genes and prostate cancer risk: a pharmacogenomic approach.

2009

In this paper, we consider the role of the genetics of inflammation in the pathophysiology of prostate cancer (PCa). This paper is not an extensive review of the literature, rather it is an expert opinion based on data from authors' laboratories on age-related diseases and inflammation. The aim is the detection of a risk profile that potentially allows both the early identification of individuals at risk for disease and the possible discovery of potential targets for medication. In fact, a major goal of clinical research is to improve early detection of age-related diseases, cancer included, by developing tools to move diagnosis backward in disease temporal course, i.e., before the clinical…

MaleCancer ResearchPathologymedicine.medical_specialtyAgingpharmacogenomicmedicine.medical_treatmentImmunologyGenomicsDiseaseBioinformaticsProstate cancerlongevitySettore MED/05 - Patologia ClinicaImmunology and AllergyMedicineHumansGenetic Predisposition to DiseaseSettore MED/04 - Patologia GeneraleInflammationPolymorphism Geneticbusiness.industryCancerProstatic NeoplasmsImmunotherapyprostate cancermedicine.diseaseClinical researchOncologyageingPharmacogeneticsPharmacogenomicsgeneticInflammation MediatorsbusinessPharmacogeneticsCancer immunology, immunotherapy : CII
researchProduct

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

2012

Background: In the MACRO study, patients with metastatic colorectal cancer (mCRC) were randomised to first-line treatment with 6 cycles of capecitabine and oxaliplatin (XELOX) plus bevacizumab followed by either single-agent bevacizumab or XELOX plus bevacizumab until disease progression. An additional retrospective analysis was performed to define the prognostic value of tumour KRAS status on progression-free survival (PFS), overall survival (OS) and response rates. Methodology/Principal Findings: KRAS data (tumour KRAS status and type of mutation) were collected by questionnaire from participating centres that performed KRAS analyses. These data were then cross-referenced with efficacy da…

MaleOncologyOrganoplatinum Compoundsendocrine system diseasesEpidemiologyColorectal cancer:Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]DeoxycytidineMetastasis:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Antineoplastic Combined Chemotherapy ProtocolsPathologyMedicineNeoplasm Metastasisgeneslcsh:Sciencemediana edad:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Clinical Protocols::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols [Medical Subject Headings]Aged 80 and overanciano:Chemicals and Drugs::Organic Chemicals::Organometallic Compounds::Organoplatinum Compounds [Medical Subject Headings]Cancer Risk FactorsClinical Pharmacologyprotocolos de quimioterapia antineoplásica combinadaColon AdenocarcinomaPronósticoCombination chemotherapyadultoPrognosisBevacizumabOxaliplatinpronósticoOncologyMedicineOncology Agentsmedicine.medical_specialty:Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation [Medical Subject Headings]FluorouraciloBevacizumab:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Pyrimidines::Pyrimidine Nucleosides::Cytidine::Deoxycytidine [Medical Subject Headings]:Check Tags::Male [Medical Subject Headings]Molecular GeneticsCapecitabine:Chemicals and Drugs::Amino Acids Peptides and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies Monoclonal::Antibodies Monoclonal Humanized [Medical Subject Headings]Gastrointestinal TumorsGenetics:Named Groups::Persons::Age Groups::Adult [Medical Subject Headings]HumansClinical TrialsBiologyneoplasmsCapecitabineAgedlcsh:R:Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [Medical Subject Headings]:Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Genes Neoplasm::Oncogenes::Proto-Oncogenes::Genes ras [Medical Subject Headings]medicine.diseasedigestive system diseasesOxaliplatin:Check Tags::Female [Medical Subject Headings]PharmacogeneticsMutationlcsh:QfluorouraciloMultivariate analysisDesoxicitidinahumanosCancer Treatment:Named Groups::Persons::Age Groups::Adult::Aged::Aged 80 and over [Medical Subject Headings]lcsh:Medicinemedicine.disease_causeNeoplasias colorrectalesSurgical oncologyBasic Cancer Research:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Pyrimidines::Pyrimidinones::Uracil::Fluorouracil [Medical Subject Headings]Clinical Trials (Cancer Treatment)metástasis neoplásicaMetástasis neoplásicaMultidisciplinaryMiddle AgedGenetic EpidemiologyProtocolos de quimioterapia antineoplásica combinadaFemaleAntiangiogenesis TherapyFluorouracilKRASColorectal NeoplasmsResearch Articlemedicine.drugAdultDrugs and DevicesClinical Pathologyneoplasias colorrectalesClinical Research DesignGenetic Causes of CancerAntibodies Monoclonal HumanizedAntibodiesRectal CancerAntibody TherapyDiagnostic MedicineInternal medicine:Diseases::Neoplasms::Neoplastic Processes::Neoplasm Metastasis [Medical Subject Headings]:Named Groups::Persons::Age Groups::Adult::Aged [Medical Subject Headings]mutaciónClinical GeneticsMutaciónbusiness.industryPharmacoepidemiologyCancers and NeoplasmsHuman GeneticsChemotherapy and Drug TreatmentdesoxicitidinaGenes rasanticuerposGenetics of Diseasebusinesscompuestos organoplatinoPLoS ONE
researchProduct

A comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation

2012

Translational read-through-inducing drugs (TRIDs) promote read-through of nonsense mutations, placing them in the spotlight of current gene-based therapeutic research. Here, we compare for the first time the relative efficacies of new-generation aminoglycosides NB30, NB54 and the chemical compound PTC124 on retinal toxicity and read-through efficacy of a nonsense mutation in the USH1C gene, which encodes the scaffold protein harmonin. This mutation causes the human Usher syndrome, the most common form of inherited deaf-blindness. We quantify read-through efficacy of the TRIDs in cell culture and show the restoration of harmonin function. We do not observe significant differences in the read…

MaleRetinal DisorderUsher syndromemedia_common.quotation_subjectNonsenseNonsense mutationPeptide Chain Elongation TranslationalCell Cycle ProteinsIn Vitro TechniquesBiologyPharmacologymedicine.disease_causeRetinaCell LineMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRetinal DiseasesIn vivoretinitis pigmentosaRetinitis pigmentosaotorhinolaryngologic diseasesmedicineAnimalsHumansResearch ArticlesAdaptor Proteins Signal Transducingpharmacogenetics030304 developmental biologymedia_commonOxadiazoles0303 health sciencesMutationsensoneuronal degenerationRetinalmedicine.diseasedrug therapy3. Good healthMice Inbred C57BLCytoskeletal ProteinsAminoglycosideschemistryCodon NonsenseMolecular MedicineFemaleUsher syndrome030217 neurology & neurosurgeryEMBO Molecular Medicine
researchProduct

Genetic Polymorphisms and Individualized Tacrolimus Dosing

2010

Background. Genetic polymorphisms of metabolism enzymes or intestinal drug transporters may affect pharmacokinetic responses to immunosuppressive drugs in renal transplant recipients. We sought to identify the frequency of genetic polymorphisms and their importance for individualization of tacrolimus doses. Patients and Methods. We performed an observational study in 35 renal transplant recipients treated with tacrolimus, mycophenolate mofetil, and corticosteroids. Tacrolimus concentrations were determined by immunoanalysis (IMx method; Abbott Diagnostics, Abbott Park, Ill), on 11 blood samples per patient during the first 6 weeks after renal transplantation. For each patient, we calculated…

Malemedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BBiologyPolymorphism Single NucleotideGastroenterologyTacrolimusIntestinal absorptionCohort StudiesPharmacokineticsInternal medicinemedicineCytochrome P-450 CYP3AHumansATP Binding Cassette Transporter Subfamily B Member 1Antibacterial agentTransplantationProtein synthesis inhibitorMiddle AgedTacrolimusCalcineurinTransplantationsurgical procedures operativePharmacogeneticsImmunologyFemaleSurgeryImmunosuppressive AgentsPharmacogeneticsTransplantation Proceedings
researchProduct

Variants in COMT and spontaneous smoking cessation: retrospective cohort analysis of 925 cessation events

2009

Genome-wide studies have identified single nucleotide polymorphisms associated with smoking behaviour and nicotine dependence. Less is known about genetic determinants of smoking cessation, but rs4680 in COMT has recently been shown to explain a substantial proportion of the variation in cessation in the general population. We attempted to replicate the reported, clinically relevant effect in a population-based retrospective cohort analysis of 1443 ever-heavy smokers, of whom 925 had reached abstinence. In Cox regression models, neither rs4680 nor two polymorphisms nearby were associated with smoking cessation. The adjusted relative cessation rate (95% confidence interval) in rs4680 methion…

Malemedicine.medical_specialtyGenotypemedia_common.quotation_subjectmedicine.medical_treatmentPopulationPharmacologyCatechol O-MethyltransferaseCohort StudiesInternal medicineGeneticsHumansMedicineGeneral Pharmacology Toxicology and PharmaceuticseducationMolecular BiologyGenetics (clinical)AgedProportional Hazards ModelsRetrospective Studiesmedia_commoneducation.field_of_studybusiness.industryProportional hazards modelHomozygoteSmokingGenetic VariationRetrospective cohort studyMiddle AgedAbstinenceConfidence intervalRegression AnalysisMolecular MedicineSmoking cessationFemaleSmoking CessationbusinessPharmacogeneticsrs4680Pharmacogenetics and Genomics
researchProduct

Efavirenz and the CNS: what we already know and questions that need to be answered

2015

The NNRTI efavirenz has long been one of the most frequently employed antiretroviral drugs in the multidrug regimens used to treat HIV infection, in accordance with its well-demonstrated antiretroviral efficacy and favourable pharmacokinetics. However, growing concern about its adverse effects has sometimes led to efavirenz being replaced by other drugs in the initial treatment selection or to switching of therapy to efavirenz-free regimens in experienced patients. Neurological and neuropsychiatric reactions are the manifestations most frequently experienced by efavirenz-treated patients and range from transitory effects, such as nightmares, dizziness, insomnia, nervousness and lack of conc…

Microbiology (medical)DrugCentral Nervous SystemCyclopropanesPsychosismedicine.medical_specialtyEfavirenzAnti-HIV Agentsmedia_common.quotation_subjectHIV InfectionsPolymorphism Single Nucleotidechemistry.chemical_compoundimmune system diseasesCentral Nervous System DiseasesAntiretroviral Therapy Highly ActivemedicineAnimalsCytochrome P-450 Enzyme InhibitorsHumansPharmacology (medical)Adverse effectIntensive care medicineSuicidal ideationmedia_commonPharmacologybusiness.industryNeurotoxicityvirus diseasesmedicine.diseaseBenzoxazinesCytochrome P-450 CYP2B6Disease Models AnimalInfectious DiseaseschemistryPharmacogeneticsAlkynesReverse Transcriptase Inhibitorsmedicine.symptomCNSEfavirenzbusinessNeurocognitivePharmacogenetics
researchProduct